Resmed Inc.

RMD

NYSE; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0000943819

A

strongest fifth of 370 graded peers in healthcare

rank 52 of 370; percentile 13.8; sampling error 2.5 points; lower is stronger


A B C D E

A, the bull




Scoreboard	
Profitability	B/C percentile 37.5
Solvency	B percentile 27.8
Growth and financing	B/C percentile 38.2
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $9.0B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered; fortress balance sheet not computable: dilution, distress
Inputs computable	11 of 14
Graded from	filings received through Aug 13, 2026 85 days before the rescan; latest periodic filing 10-Q received Oct 30, 2026
Last close	$239.36 2026-11-05; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Aug 13, 2026

We are a global leader in digital health and cloud-connected medical devices. We design innovative technology to empower people to live happier, healthier lives. Our artificial intelligence, or AI, powered digital health solutions, cloud-connected devices and intelligent software are designed to make home healthcare more personalized, accessible and effective. By enabling better care, our products improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 37.5						
Gross profitability	38.5%	32.3%		35.2	365	2026-06-30
Return on invested capital	27.4%	9.3%		9.6	74	2026-06-30
Accruals ratio	(3.3%)	(6.6%)		69.9	802	2026-06-30
Gross margin stability, five years	2.0 pts	2.8 pts		35.3	242	2026-06-30

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Solvency, sleeve percentile 27.8						
Twelve-month failure probability	not computable	0.07%				
firm-wide XBRL shares cannot be assigned to one ticker class						
Altman Z double-prime	9.10	(0.37)		10.1	747	2026-06-30
Net debt to EBITDA	(0.51x)	1.82x		18.9	75	2026-06-30
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2021-06-30; latest annual assets end 2026-06-30						
Current ratio	3.10x	2.94x		54.5	828	2026-06-30
Growth and financing, sleeve percentile 38.2						
Revenue growth, three-year compound	10.2%	10.0%		50.4	412	2026-06-30
Free cash flow growth, three-year compound	42.2%	10.9%		17.9	96	2026-06-30
Reinvestment rate	26.6%	37.1%		52.9	105	2026-06-30
Asset growth, three years	9.9%	2.2%		31.8	696	2026-06-30
Net share issuance, one year	not computable	2.5%				
firm-wide XBRL shares cannot be assigned to one ticker class						


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 1,069,819,000 USD; Altman Z is not used

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
47	RxSight, Inc. (RXST)	12.5	A	fortress balance sheet
48	Insulet Corp. (PODD)	12.7	A	
49	Utah Medical Products Inc. (UTMD)	13.0	A	fortress balance sheet
50	Tarsus Pharmaceuticals, Inc. (TARS)	13.3	A	fortress balance sheet
51	Ardelyx, Inc. (ARDX)	13.6	A	
52	Resmed Inc. (RMD)	13.8	A	fortress balance sheet
53	Gyre Therapeutics, Inc. (GYRE)	14.1	A	fortress balance sheet
54	Janux Therapeutics, Inc. (JANX)	14.4	A	
55	Treace Medical Concepts, Inc. (TMCI)	14.6	A	
56	Edwards Lifesciences Corp. (EW)	14.9	A	
57	Lantheus Holdings, Inc. (LNTH)	15.2	A	

What the price implies

at the 2026-11-05 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(9.5%)	(2.1%)	44
Distance from 52-week high	(13.3%)	(30.4%)	71
EBIT to enterprise value	not computable	(1.5%)	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.29	
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	21.4%	
Relative strength against the sector, log excess return	(0.27)	(0.19)	44

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-06-30	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$1.0B
Operating cash flow, four quarters	$1.8B
Months of runway	not finite
Days since last periodic filing	7 (10-Q received Oct 30, 2026)
Median daily dollar volume, 63 sessions	$267.0M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$3.5B	2026-06-30	2026-08-13	10-K	26-000047
2	assets	us-gaap:Assets	$9.0B	2026-06-30	2026-08-13	10-K	26-000047
3	operating income	us-gaap:OperatingIncomeLoss	$1.9B	2026-06-30	2026-08-13	10-K	26-000047
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$1.9B	2026-06-30	2026-08-13	10-K	26-000047
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$396.1M	2026-06-30	2026-08-13	10-K	26-000047
6	total debt	us-gaap:LongTermDebt	$399.4M	2026-06-30	2026-08-13	10-K	26-000047
7	book equity	us-gaap:StockholdersEquity	$6.6B	2026-06-30	2026-08-13	10-K	26-000047
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.5B	2026-06-30	2026-08-13	10-K	26-000047
9	total debt	us-gaap:LongTermDebt	$658.4M	2025-06-30	2026-08-13	10-K	26-000047
10	book equity	us-gaap:StockholdersEquity	$6.0B	2025-06-30	2026-08-13	10-K	26-000047
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.2B	2025-06-30	2026-08-13	10-K	26-000047
12	net income	us-gaap:NetIncomeLoss	$1.5B	2026-06-30	2026-08-13	10-K	26-000047
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.8B	2026-06-30	2026-08-13	10-K	26-000047
14	assets	us-gaap:Assets	$8.2B	2025-06-30	2026-08-13	10-K	26-000047
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$5.7B	2026-06-30	2026-08-13	10-K	26-000047
16	gross profit	us-gaap:GrossProfit	$3.1B	2025-06-30	2026-08-13	10-K	26-000047
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$5.1B	2025-06-30	2026-08-13	10-K	26-000047
18	gross profit	us-gaap:GrossProfit	$2.7B	2024-06-30	2026-08-13	10-K	26-000047
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$4.7B	2024-06-30	2026-08-13	10-K	26-000047
20	gross profit	us-gaap:GrossProfit	$2.4B	2023-06-30	2025-08-08	10-K	25-000035
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$4.2B	2023-06-30	2025-08-08	10-K	25-000035
22	gross profit	us-gaap:GrossProfit	$2.0B	2022-06-30	2024-08-09	10-K	24-000013
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.6B	2022-06-30	2024-08-09	10-K	24-000013
24	current assets	us-gaap:AssetsCurrent	$4.3B	2026-06-30	2026-08-13	10-K	26-000047
25	current liabilities	us-gaap:LiabilitiesCurrent	$1.4B	2026-06-30	2026-08-13	10-K	26-000047

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$7.3B	2026-06-30	2026-08-13	10-K	26-000047
27	liabilities	us-gaap:Liabilities	$2.4B	2026-06-30	2026-08-13	10-K	26-000047
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$201.3M	2026-06-30	2026-08-13	10-K	26-000047
29	operating income	us-gaap:OperatingIncomeLoss	$903.7M	2021-06-30	2023-08-11	10-K	23-000011
30	interest expense	us-gaap:InterestExpense	$24.0M	2021-06-30	2021-08-17	10-K	21-000017
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$156.3M	2026-06-30	2026-08-13	10-K	26-000047
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.8B	2025-06-30	2026-08-13	10-K	26-000047
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$89.9M	2025-06-30	2026-08-13	10-K	26-000047
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.4B	2024-06-30	2026-08-13	10-K	26-000047
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$99.5M	2024-06-30	2026-08-13	10-K	26-000047
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$693.3M	2023-06-30	2025-08-08	10-K	25-000035
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$119.7M	2023-06-30	2025-08-08	10-K	25-000035
38	current assets	us-gaap:AssetsCurrent	$3.5B	2025-06-30	2026-08-13	10-K	26-000047
39	current liabilities	us-gaap:LiabilitiesCurrent	$1.0B	2025-06-30	2026-08-13	10-K	26-000047
40	assets	us-gaap:Assets	$6.9B	2024-06-30	2025-08-08	10-K	25-000035
41	assets	us-gaap:Assets	$6.8B	2023-06-30	2024-08-09	10-K	24-000013

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.